InflaRx (IFRX) Other Accumulated Expenses (2017 - 2018)
InflaRx (IFRX) posted Other Accumulated Expenses of $189757.7 for Q2 2018, down 16.5% sequentially from $227244.5 in Q4 2017.
InflaRx (IFRX) Other Accumulated Expenses (2017 - 2018) Analysis & Trends
InflaRx has reported Other Accumulated Expenses for 2 years, with the latest figure at $189757.7 in Q2 2018.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $189757.7 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $189757.7 (changed N/A YoY) and the FY2017 annual result came in at $217960.7, changed N/A from the prior year.
- Other Accumulated Expenses retreated to $189757.7 in Q2 2018 per IFRX's latest filing, from $227244.5 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $227244.5 in Q4 2017 and troughed at $189757.7 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 189,757.66 |
| Dec 31, 2017 | 227,244.48 |